Devon Energy, CRISPR Therapeutics, And Bullish On Berkshire Succession: CNBC's 'Final Trades'

On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners said CRISPR Therapeutics AG CRSP reported strong quarterly earnings.

CRISPR Therapeutics posted a Q1 loss of 67 cents per share, narrower than market expectations for a loss of $1.76 per share.

Analysts have a consensus Buy rating on CSP, according to Benzinga's analyst ratings data.

Jenny Harrington of Gilman Hill Asset Management said Devon Energy Corporation DVN reported a great quarter on Monday. The company also increased its share repurchase authorization by 50%.

The oil producer reported adjusted earnings of $1.46 per share, which beat estimates of $1.38 per share. Oil production averaged 320,000 barrels per day in the quarter, which came in 2,000 barrels per day above the company’s midpoint guidance.

Don’t forget to check out our premarket coverage here

Josh Brown of Ritholtz Wealth Management said he is feeling very good about Berkshire Hathaway Inc’s (NYSE: BRK-B) succession.

Warren Buffett's Berkshire reported a profit of $35.5 billion for the first quarter.

Price Action: Berkshire Hathaway shares fell 0.4% to settle at $324.87 on Tuesday. Devon Energy fell 3.6% to $49.17, while CRISPR Therapeutics jumped 13.3% to settle at $63.42 on Tuesday.

Check This Out: Wall Street's Most Accurate Analysts Say Hold These 3 Financial Stocks Delivering High-Dividend Yields

Photo: Shutterstock